Company: TAK
Filing Date: 2025-06-25
Form Type: 20-F
Source: 0001395064-25-000095
Chunk: 125

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-25
Form: 20-F
Item: Item 5
Chunk 125
---
463.9 billion (JPY -143.2 billion). The decrease was mainly due to a decrease in Acquisition of Intangible Assets (JPY -187.7 billion)*1.

*1 USD 3.0 billion was paid to Nimbus for the acquisition of TAK-279 in the fiscal year ended March 31, 2023 while USD 1.0 billion and USD 0.4 billion were paid to Nimbus for the acquisition of TAK-279 and to HUTCHMED for the exclusive license agreement for FRUZAQLA, respectively, in the fiscal year ended March 31, 2024.

Net cash used in financing activities. Net cash used in financing activities for the fiscal year ended March 31, 2024 was JPY 354.4 billion (JPY -354.7 billion). The decrease was mainly due to a net increase of JPY 237.0 billion in commercial paper drawings, a net decrease of JPY 60.9 billion in redemption of bonds and the settlement of cross currency interest rate swaps related to bonds in the fiscal year ended March 31, 2024.

Table of Contents

Supplemental Discussion: Free Cash Flow and Adjusted Free Cash Flow (Non-IFRS Measures)

Free cash flow and Adjusted Free Cash Flow are non-IFRS measures, see “ Annex to Item 5. Certain Supplemental Non-IFRS Measures as Defined and Presented by Takeda - Free Cash Flow and Adjusted Free Cash Flow” for further information. The most directly comparable measures under IFRS for Free Cash Flow and Adjusted Free Cash Flow is Net Cash from Operating Activities.

                                                 For the Year Ended March 31,                        
                                                 2023                               2024       2025  
 ─────────────────────────────────────────────────────────────────────────────────────────────────────
                                                 (billions of yen)                                   
  Net cash from operating activities (IFRS)      ¥                                     ¥          ¥  
  Free cash flow (non-IFRS)                      836.5                             540.9      856.4  
  Adjusted free cash flow (non-IFRS)             446.2                             283.4      769.0  

Fiscal Year Ended March 31, 2025 compared with the Fiscal Year Ended March 31, 2024

Free Cash Flow for the fiscal year ended March 31, 2025 was JPY 856.4 billion (JPY +315.